Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.Objective To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.Design Randomized double-blind controlled cross-over trial.Setting Community and hospital-based.Participants Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m(2)). All volunteers completed the study protocol.Interventions Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.Measurements (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.Results Oxyntomodulin administration reduced energy intake at the study meal by 128+/-29 kcal (P=0.0006) or 17.3+/-5.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). A reduction in body weight of 0.5+/-0.2% was observed during the oxyntomodulin administration period (P=0.0232).Conclusion Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2006
In the citing paper
“ACCORD, like the UKPDS, demonstrated that improved glucose control reduced microvascular complications126”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [126]
Citations
Cites
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
Prevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Role of Nonexercise Activity Thermogenesis in Resistance to Fat Gain in Humans
Levine, J. A., Eberhardt, N. L., & Jensen, M. D. (1999) · Science · doi:10.1126/science.283.5399.212 · Cited by 997
Reliability and validity of the combined heart rate and movement sensor Actiheart
Brage, S., Brage, N., Franks, P. W., Ekelund, U., & Wareham, N. J. (2005) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602118 · Cited by 667
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P. J. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2984 · Cited by 534
Self-citationBrage, S., Brage, N., Franks, P. W., Ekelund, U., Wong, M.-Y., Andersen, L. B., Froberg, K., & Wareham, N. J. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00703.2003 · Cited by 473
Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 472
Self-citation
Cited by
Items 101–200 of 365
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
Papamargaritis, D., & le Roux, C. W. (2021) · Nutrients · doi:10.3390/nu13030762 · Cited by 68
“Exogenous administration of OXM reduces food intake and increases energy expenditure in humans [117,118].”
BackgroundMechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity
Vincent, R. P., Ashrafian, H., & le Roux, C. W. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1118 · Cited by 75
Roth, C. L., & Reinehr, T. (2010) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2009.265 · Cited by 75
“In a recent 4-day human study, oxyntomodulinnotonlypromotedweightlossbutincreased energy expenditure by more than 25%.(113) GLP-1 and the amylin analogue pramlintide appear to decrease weight in patients with T2DM, which is an important secondary goal in treating these patients.”
BackgroundNielsen, M. S., Ritz, C., Wewer Albrechtsen, N. J., Holst, J. J., le Roux, C. W., & Sjödin, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa061 · Cited by 65
DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives
Santoprete, A., Capitò, E., Carrington, P. E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., et al. (2011) · Journal of Peptide Science · doi:10.1002/psc.1328 · Cited by 65
Obesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64
Self-citationJungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
Obesity pharmacotherapy: What is next?
Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 62
“In humans, IV infusion of OXM suppressed appetite and feeding and increased energy expenditure (Batterham et al., 2003a; Wynne et al., 2006).”
BackgroundMartinou, E., Stefanova, I., Iosif, E., & Angelidi, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063339 · Cited by 69
“Studies have also reported that the exogenous administration of OXM not only reduces food intake but also increases energy expenditure in humans [215,216].”
BackgroundThe role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes
Adamska, E., Ostrowska, L., Górska, M., & Krętowski, A. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.42498 · Cited by 60
“4% (as opposed to most weight loss treatments) [64].”
BackgroundHellström, P. M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835d9ff8 · Cited by 74
“However, at variance with GLP-1, oxyntomodulin increases energy loss and suppresses ghrelin release [18,26,27], which would benefit weight control.”
BackgroundSowden, G. L., Drucker, D. J., Weinshenker, D., & Swoap, S. J. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00405.2006 · Cited by 57
“15 Discussion While the effects of OXM on food intake have been investigated extensively (2, 11, 14, 17, 45, 46), little is known about the effects of OXM on the cardiovascular system.”
BackgroundInfluentialShankar, S. S., Shankar, R. R., Mixson, L. A., Miller, D. L., Pramanik, B., O’Dowd, A. K., Williams, D. M., Frederick, C. B., Beals, C. R., Stoch, S. A., et al. (2018) · Diabetes · doi:10.2337/db17-1331 · Cited by 55
“In similar elegantly designed and executed mechanistic studies in the same series, Bloom and colleagues (6,7) demonstrated that OXM can suppress appetite but, unlike GLP-1, increase energy expenditure as well, findings that suggest contributions from both GLP-1R and GCGR activation.”
BackgroundInfluentialKerr, B. D., Flatt, P. R., & Gault, V. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.010 · Cited by 56
The Pharmacological Treatment and Management of Obesity
Hussain, S. S., & Bloom, S. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2243 · Cited by 54
“Oxyntomodulin inhibits food intake and increases energy expenditure in humans.(67) TKS1225 is a long-acting synthetic analog of oxyntomodulin and is in phase 1 trials.”
BackgroundSelf-citationGut hormones as therapeutic agents in treatment of diabetes and obesity
Tan, T., & Bloom, S. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.005 · Cited by 66
Self-citationProblem or solution: The strange story of glucagon
Scott, R. V., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.013 · Cited by 54
“Moreover, this weight loss is not accompanied by any deterioration in glucose tolerance [78,79].”
BackgroundMethodSelf-citationGastrointestinal satiety signals
Chaudhri, O. B., Field, B. C. T., & Bloom, S. R. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.235 · Cited by 68
Self-citationHormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
“OXM decreases body weight by lowering food intake and increasing energy expenditure in both rodents and humans [114,115].”
BackgroundDuca, F. A., & Covașă, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000529 · Cited by 57
“most of these peptides in obesity treatment remains uncertain and is still under consideration, the effects of OXM, which has potent anorectic, incretin and energy expenditure properties((175,176)), look more promising with recent data showing decreased food intake and sustained weight loss in diet-induced obese mice…”
BackgroundDifferential effects of oxyntomodulin and GLP-1 on glucose metabolism
Du, X., Kosinski, J. R., Lao, J., Shen, X., Petrov, A., Chicchi, G. G., Eiermann, G. J., & Pocai, A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00142.2012 · Cited by 52
The Role of Gut–brain Axis in Regulating Glucose Metabolism After Acute Pancreatitis
Pendharkar, S. A., Asrani, V. M., Murphy, R., Cutfield, R. G., Windsor, J. A., & Petrov, M. S. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.63 · Cited by 56
“Several randomized trials have demonstrated that direct administration of oxyntomodulin results in a significant weight loss and reduced energy intake.(45,46) Second, increase in oxyntomodulin secretion could also be achieved indirectly by preventing bile acid absorption and thus increasing the level of cholecystokini…”
BackgroundCentral and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
Valentino, M. A., Lin, J. E., & Waldman, S. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.57 · Cited by 51
Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?
Lundqvist, M., Almby, K. E., Abrahamsson, N., & Eriksson, J. W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00457 · Cited by 60
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
Scott, R., Minnion, J., Tan, T., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2018.04.008 · Cited by 48
“Short-term studies suggest that administration of exogenous OXM can reduce body weight in humans [4,5].”
BackgroundMethodInfluentialSelf-citationSubcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents
Liu, Y. ‐., Ford, H. E., Druce, M. R., MINNION, J. S., Field, B. C. T., Shillito, J. C., Baxter, J. E., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.110 · Cited by 53
Self-citationAddressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Mittermayer, F., Caveney, E., De Oliveira, C., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2015) · Current Diabetes Reviews · doi:10.2174/1573399810666141224121927 · Cited by 47
“Additionally, it was proven to reduce food intake after an ad libitum test meal and increase energy expenditure in humans [87].”
BackgroundRegulation of appetite to treat obesity
Kim, G. W., Lin, J. E., Valentino, M. A., Colón‐González, F., & Waldman, S. A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.3 · Cited by 56
Old Paradoxes and New Opportunities for Appetite Control in Obesity
Montégut, L., López-Otín, C., Magnan, C., & Kroemer, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.005 · Cited by 48
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 51
Michalakis, K. G., & le Roux, C. W. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0698-9 · Cited by 54
“– OXM’s anorectic effect is enhanced by OXM-mediated suppression of ghrelin levels [46, 47]”
BackgroundResultElvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
“Also, co-administration of a GLP-1 agonist with a glucagon infusion resulted in an increase of energy expenditure in humans.(16) But these human studies infused GCG for only 45 to 210 minutes.”
BackgroundInfluentialBianchi, E., Carrington, P. E., Ingallinella, P., Finotto, M., Santoprete, A., Petrov, A., Eiermann, G. J., Kosinski, J. R., Marsh, D. J., Pocai, A., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.016 · Cited by 45
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
“In a randomized human trial in 2006, Wynne et al. 62 provided evidence that OXM may increase total energy expenditure.”
Xanthakos, S. A. (2008) · Pathophysiology · doi:10.1016/j.pathophys.2008.04.005 · Cited by 45
“Oxynomodulin may also have an effect on weight reduction by ncreasing spontaneous physical activity in both humans and odents [128,131].”
BackgroundThe metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 50
“Oxyntomodulin, a combined GLP-1/glucagon- receptor co-agonist, reduces body weight compared with placebo and with GLP-1 agonism in obese and overweight individuals [138, 139].”
BackgroundNew Targets for Drug Treatment of Obesity
Valsamakis, G., Konstantakou, P., & Mastorakos, G. P. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104735 · Cited by 48
The role of gut hormones in appetite regulation (review)
Maric, G. D., Gazibara, T. M., Zaletel, I. V., Labudović‐Borović, M., Tomanović, N., Ćirić, M., & Puškaš, N. (2014) · Acta Physiologica Hungarica · doi:10.1556/aphysiol.101.2014.4.1 · Cited by 56
Lockie, S. H. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12039 · Cited by 39
Kim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 45
“concurrently with GLP-1 by the L-cells, reduces food intake while increasing energy consumption and insulin secretion [12,13].”
BackgroundPosovszky, C., & Wabitsch, M. (2014) · Hormone Research in Paediatrics · doi:10.1159/000368898 · Cited by 47
The Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity
Huang, X., Dai, F. F., Gaisano, G., Giglou, K., Han, J., Zhang, M., Kittanakom, S., Wong, V., Li, W., Showalter, A. D., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1047 · Cited by 45
Vidarsdottir, S., Roelfsema, F., Streefland, T., Holst, J. J., Rehfeld, J. F., & Pijl, H. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0433 · Cited by 37
Visentin, R., Schiavon, M., Göbel, B., Riz, M., Cobelli, C., Klabunde, T., & Dalla Man, C. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13939 · Cited by 37
Lenz, A., & Diamond, F. B. (2008) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3282f43a5b · Cited by 37
Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264974 · Cited by 36
Bowels control brain: gut hormones and obesity
Bewick, G. A. (2012) · Biochemia Medica · doi:10.11613/bm.2012.032 · Cited by 36
The Role of Hormonal Factors in Weight Loss and Recidivism after Bariatric Surgery
Pedersen, S. D. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/528450 · Cited by 40
“OXM has also been shown to increase energy expenditure when administered to overweight or obese humans [15].”
BackgroundGlucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1
Tharakan, G., Tan, T., & Bloom, S. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.10.003 · Cited by 39
Self-citationZouhal, H., Sellami, M., Saeidi, A., Slimani, M., Abbassi-Daloii, A., Khodamoradi, A., El Hage, R., Hackney, A. C., & Ben Abderrahman, A. (2019) · Nutrition Reviews · doi:10.1093/nutrit/nuz005 · Cited by 35
Oxyntomodulin increases intrinsic heart rate through the glucagon receptor
Mukharji, A., Drucker, D. J., Charron, M. J., & Swoap, S. J. (2013) · Physiological Reports · doi:10.1002/phy2.112 · Cited by 34
“OXM can inhibit food intake, elevate metabolic rate, and cause weight loss when administered peripherally in humans, sparking interest in the use of OXM or related glucagon-GLP-1 receptor co-agonists as a potential therapy for obesity (Wynne et al. 2005, 2006).”
BackgroundThe forgotten members of the glucagon family
BATAILLE, D., & Dalle, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.06.010 · Cited by 35
“In addition to its action on energy intake, OXM increases energy expenditure [21].”
BackgroundAnand, U., Yiangou, Y., Akbar, A., Quick, T., MacQuillan, A. H. F., Fox, M., Sinisi, M., Korchev, Y. E., Jones, B. J., Bloom, S. R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198024 · Cited by 35
Self-citationCorbin, K. D., Carnero, E. A., Allerton, T. D., Tillner, J., Bock, C. P., Luyet, P., Göbel, B., Hall, K. D., Parsons, S. A., Ravussin, E., et al. (2023) · Obesity · doi:10.1002/oby.23633 · Cited by 32
“Both preclinical and short clinical studies of the dual GLP-1R/ GCGR agonist oxyntomodulin have shown increases in total, resting, and/or activity related EE [10, 38].”
BackgroundGut hormones: the future of obesity treatment?
McGavigan, A. K., & Murphy, K. G. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04278.x · Cited by 38
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 33
Kahleová, H., Mari, A., Nofrate, V., Matoulek, M., Kazdová, L., Hill, M., & Pelikánová, T. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.05.003 · Cited by 38
“, 2003) and to increase energy expenditure in addition to decreasing energy intake in overweight and obese humans (Wynne et al., 2006).”
BackgroundGut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 38
Self-citationPharmacological Treatment of Obesity
Kabra, D. G., Kabra, U. D., Tschöp, M. H., & Hofmann, S. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3492-4_14 · Cited by 33
“Subsequently, it was shown that thrice daily subcutaneous administration of oxyntomodulin in obese volunteers induced a 26% rise in energy expenditure over 4 days, in addition to a reduced food intake [ 162 ] .”
BackgroundTargeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 34
Castagneto‐Gissey, L., Mariolo, J. R. C., & Mingrone, G. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.010 · Cited by 36
“Similar mechanisms of action have been observed also in humans [31,32].”
Yang, P., Zou, H., Amso, Z., Lee, C., Huang, D., Woods, A. K., Nguyen-Tran, V. T. B., Schultz, P. G., & Shen, W. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00093 · Cited by 33
Shah, A., Dodson, W. C., Kris‐Etherton, P. M., Kunselman, A. R., Stetter, C., Gnatuk, C. L., Estes, S. J., Allison, K. C., Sarwer, D. B., Sluss, P. M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa682 · Cited by 37
Role of gastrointestinal hormones in feeding behavior and obesity treatment
Kairupan, T. S., Amitani, H., Cheng, K., Runtuwene, J., Asakawa, A., & Inui, A. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1118-4 · Cited by 41
Pimentel, G. D., Mota, J. F., & Oyama, L. M. (2009) · Revista de Nutrição · doi:10.1590/s1415-52732009000500013 · Cited by 29
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“109 More direct evidence was derived from the study performed by Cegla et al. This double-blind crossover trial, which included 13 participants, showed that simultaneous infusions of GLP-1 and GCG more significantly reduced food intake compared with GLP-1 or GCG alone.”
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
“Peripheral OXM administration reduces food intake and increases energy expenditure in rodents (Dakin et al., 2004) and humans (Wynne et al., 2006).”
BackgroundObesity Pharmacotherapy: Current Perspectives and Future Directions
Misra, M. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076322 · Cited by 36
“5%, with no change in meal palatability [135].”
BackgroundNo Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 35
Self-citationChen, Y., Smith, H., Hengist, A., Chrzanowski‐Smith, O. J., Mikkelsen, U. R., Carroll, H. A., Betts, J. A., Thompson, D., Saunders, J., & Gonzalez, J. T. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02092-4 · Cited by 29
Nogueiras, R. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0277 · Cited by 32
National survey of pediatric fever management practices among emergency department nurses.
Thomas, V., Riegel, B. J., Andrea, J., Murray, P., Gerhart, A. E., & Gocka, I. (1994) · PubMed · Cited by 32
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Αλεξιάδου, Κ., & Tan, T. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01309-9 · Cited by 27
Lynch, A. M., Pathak, N., Flatt, Y. E., Gault, V. A., O'Harte, F. P. M., Irwin, N., & Flatt, P. R. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.018 · Cited by 27
New advances in models and strategies for developing anti-obesity drugs
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.792804 · Cited by 37
“In human studies, IV infusion of OXM suppressed appetite and reduced feeding, while also increasing energy expenditure [105,106].”
BackgroundGribble, F. M., Reimann, F., & Roberts, G. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00002-5 · Cited by 30
The gut sensor as regulator of body weight
Reinehr, T., & Roth, C. L. (2014) · Endocrine · doi:10.1007/s12020-014-0518-1 · Cited by 30
Kokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
The molecular signaling of exercise and obesity in the microbiota-gut-brain axis
Ribeiro, F. M., Silva, M. A., Lyssa, V., Marques, G., Lima, H. K., Franco, O. L., & Petriz, B. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927170 · Cited by 30
Revisiting Resting Metabolic Rate: What is the Relation to Weight Fluctuations?
Argyrakopoulou, G., Fountouli, N., Dalamaga, Μ., & Kokkinos, A. D. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00528-x · Cited by 28
“It did not affect resting EE but increased activity-related EE aiding to WL [43].”
Neuroendocrine regulation of food intake
Chaptini, L. A., & Peikin, S. R. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282f3f4d8 · Cited by 26
The effects of pancreatic polypeptide on locomotor activity and food intake in mice
Liu, Y.-L., Semjonous, N. M., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.160 · Cited by 27
Self-citationAppetite and Body Weight Regulation
Vasselli, J. R. (2012) · Wiley eBooks · doi:10.1002/9781394323142.ch8 · Cited by 26
Gastrointestinal Symptoms and Diseases Related to Obesity: An Overview
Foxx–Orenstein, A. E. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.006 · Cited by 26
Elvert, R., Bossart, M., Herling, A. W., Weiss, T., Zhang, B., Kannt, A., Wagner, M., Haack, T., Evers, A., Dudda, A., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00399 · Cited by 24
Oxyntomodulin May Distinguish New-Onset Diabetes After Acute Pancreatitis From Type 2 Diabetes
Bharmal, S. H., Cho, J., Stuart, C. E., Ramos, G. C. A., Ko, J., & Petrov, M. S. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000132 · Cited by 24
Association of Gut Hormones and Microbiota with Vascular Dysfunction in Obesity
Rovella, V., Rodia, G., Daniele, F. D., Cardillo, C., Campia, U., Noce, A., Candi, E., Della‐Morte, D., & Tesauro, M. (2021) · Nutrients · doi:10.3390/nu13020613 · Cited by 25
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 29
“Oxyntomodulin (which is a natural GLP-1 co-agonist) had significant effects on energy intake in humans (Cohen et al., 2003) and reduced weight and energy intake when administered SQ in a randomized, controlled trial (Wynne et al., 2005; Wynne et al., 2006).”
BackgroundCombination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23
Yazawa, R., Ishida, M., Balavarca, Y., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15064 · Cited by 23
Jones, B. J., Sands, C. J., Αλεξιάδου, Κ., MINNION, J. S., Tharakan, G., Behary, P., Ahmed, A., Purkayastha, S., Lewis, M. R., Bloom, S. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab608 · Cited by 21
Self-citationHeard, K. R., Wu, W., Li, Y., Zhao, P., Woźnica, I., Lai, J. H.-S., Beinborn, M., Sanford, D. G., DiMare, M. T., Chiluwal, A. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400423p · Cited by 26
Gut–brain cross-talk in appetite regulation
Cegla, J., Tan, T., & Bloom, S. R. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833b64a3 · Cited by 25
Self-citationŠestan-Peša, M., & Horváth, T. L. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.12.003 · Cited by 22
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity
Soni, H. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.08.005 · Cited by 24
“OXM was also proven to reduce food intake and energy expenditure in humans [19,20].”
BackgroundPhysiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake
Elliott, J. A., Reynolds, J. V., le Roux, C. W., & Docherty, N. G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1245140 · Cited by 22
“In addition, overweight and obese subjects who received preprandial subcutaneous OXM over a 4-day period demonstrated modest but significant weight loss, associated with a reduction in ad libitum food intake and an increase in activityrelated energy expenditure, without a change in resting energy expenditure [203].”
BackgroundAppetite and Hedonism: Gut Hormones and the Brain
Simpson, K. A., & Bloom, S. R. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.08.001 · Cited by 26
Self-citationScott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 20
“It also appears to have few side effects (Wynne et al., 2005, 2006).”
BackgroundInfluentialSelf-citationHormonal regulation of appetite
Bloom, S. R. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00320.x · Cited by 26
“adiponectin) have also been shown to affect food intake and this group of hormones is called the ‘adipokines’ (7) (also see contribution by Trayhurn).”
BackgroundSelf-citation
Metadata
- Authors
- Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Bloom, S R
- Venue
- International Journal of Obesity
- Published
- 2006-04-18
- Volume
- 30
- Issue
- 12
- Pages
- 1729-1736
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2135978651
- Cited by
- 363
- References
- 32
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 22 · 2022: 15 · 2021: 22 · 2020: 18 · 2019: 14 · 2018: 21 · 2017: 15 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 32 · 2012: 24
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, energy expenditure, energy intake, obesity, overweight, obesity treatment, physical activity, weight loss, negative energy balance, GLP-1 receptor agonists
- MeSH terms
- Adult, Blood Pressure, Energy Intake, Double-Blind Method, Energy Metabolism, Female, Heart Rate, Humans, Injections, Subcutaneous, Insulin, Male, Middle Aged, Obesity, Self Administration, Body Mass Index, Cross-Over Studies, Anti-Obesity Agents, Overweight, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.